Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2b, Randomized, Double Blind, Placebo Controlled Active Comparator, Multicenter Study To Compare 5 Dose Regimens Of CP- 690,550 And Adalimumab Versus Placebo, Administered For 6 Months In The Treatment Of Subjects With Active Rheumatoid Arthritis
Brief Summary: The purpose of this study is to determine the effectiveness and safety, over 6 months, of 5 doses of CP-690,550 for the treatment of adults with active rheumatoid arthritis. Five out of seven subjects will receive CP-690,550. One out of seven will receive adalimumab (Humira®) and one out of seven will only receive inactive substances (placebo.)


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: JNJ-54781532 150 mg once daily | Arm Label: JNJ-54781532 25 mg once daily; Type: EXPERIMENTAL; Interventions: Drug: JNJ-54781532 25 mg once daily | Arm Label: JNJ-54781532 75 mg once daily; Type: EXPERIMENTAL; Interventions: Drug: JNJ-54781532 75 mg once daily | Arm Label: JNJ-54781532 150 mg once daily; Type: EXPERIMENTAL; Interventions: Drug: JNJ-54781532 150 mg once daily | Arm Label: JNJ-54781532 75 mg twice daily; Type: EXPERIMENTAL; Interventions: Drug: JNJ-54781532 75 mg twice daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: JNJ-54781532 25 mg once daily; Assigned to Arm(s): JNJ-54781532 25 mg once daily | Intervention Type: DRUG; Name: JNJ-54781532 75 mg once daily; Assigned to Arm(s): JNJ-54781532 75 mg once daily | Intervention Type: DRUG; Name: JNJ-54781532 150 mg once daily; Assigned to Arm(s): JNJ-54781532 150 mg once daily, Placebo | Intervention Type: DRUG; Name: JNJ-54781532 75 mg twice daily; Assigned to Arm(s): JNJ-54781532 75 mg twice daily
B: Arm Label: CP-690,550 5 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,500 5 mg | Arm Label: CP-690,550 10 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 10 mg | Intervention Type: DRUG; Name: CP-690,500 5 mg; Assigned to Arm(s): CP-690,550 5 mg | Intervention Type: DRUG; Name: CP-690,550 10 mg; Assigned to Arm(s): CP-690,550 10 mg
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690-550 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: CP-690-550 | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: CP-690-550 | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 6; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 7; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: CP-690-550; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: CP-690-550; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: CP-690-550; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 7
D: Arm Label: tofacitinib 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: tofacitinib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: tofacitinib; Assigned to Arm(s): tofacitinib 10 mg BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C